Register Login
Register to leave comments
  • News bot Oct. 2, 2025, 3:32 p.m.

    📋 EyePoint Pharmaceuticals, Inc. (EYPT) - Clinical Trial Update

    Filing Date: 2022-07-18

    Accepted: 2022-07-18 16:54:15

    Event Type: Clinical Trial Update

    Event Details:

    EyePoint Pharmaceuticals Inc (EYPT) Announces Clinical Trial Update EyePoint Pharmaceuticals Inc (EYPT) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: anticipated, million
    • Diseases/Conditions: DEXYCU after December 31, its lead pipeline program
    • Clinical Stage: Clinical Trial, Phase 1
    • Collaboration: EYPT
    • Updated Timeline: Q2 2021, Q3 2022
      • targeting wet age-related macular degeneration. The proven Durasert drug delivery platform has been safely administered to thousands of patients' eyes across four U.S. FDA approved products, including YUTIQ® for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, which is currently marketed by the Company. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts. Forward Looking Statements EYEPOINT PHARMACEUTICALS SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION ACT OF 1995
      • anticipated in Q3 2022
      • planned for diabetic macular edema in 2023

    🔬 Clinical Development Pipeline (EyePoint Pharmaceuticals, Inc.):

    Product Type Development Stage Therapeutic Area Source
    EYP-1901 DRUG Phase PHASE2 Wet Age-related Macular Degeneration ClinicalTrials.gov
    Aflibercept 2mg/0.05mL Inj,Oph DRUG Phase PHASE2 Wet Age-related Macular Degeneration ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: EyePoint Pharmaceuticals Inc
    • CIK: 0001314102
    • Ticker Symbol: EYPT
    • Period End Date: 2022-07-18
    • Document Type: 8-K

Search

News categories